7 October 2015 - Patient input is a valued aspect of CADTH drug review programs. CADTH seeks input from patient groups, rather than from individuals, to encourage diversity of voices and experiences.

Based on stakeholder feedback received in May 2015, CADTH is pleased to announce that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately.

In summer 2013, CADTH introduced a pilot process within CDR to receive individual patient input. Under the pilot, CDR accepts input from individual patients and caregivers when there is no patient group representing those with a condition for which a drug under review is indicated.

Now, as part of our efforts to align the CDR and pCODR programs and to build on best practices, pCODR will accept patient input from individual patients and caregivers when there is no patient advocacy group representing patients with the particular tumour for which a drug under review is used.

For more details, go to: https://www.cadth.ca/cdr-update-issue-113